AxoGen, Inc. ( AXGN ) NASDAQ Capital Market

Cena: 16.25 ( 2.59% )

Aktualizacja 08-22 21:58
NASDAQ Capital Market
Branża: Medical - Devices
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Axogen, Inc., wraz z spółkami zależnymi, rozwija i sprzedaje roztwory chirurgiczne uszkodzenia fizycznego lub przecięcia nerwów obwodowych. Produkty firmy obejmują przeszczep nerwu Avance, biologicznie aktywny przeszczep nerwu ludzkiego do mostkowania nerwów mostkowanych bez współistniejących związanych z drugim miejscem chirurgicznym; Axoguard złącze nerwowe, wieźca podśluzówkowa macierz zewnątrzkomórkowa (ECM) pomoc w zakresie bez napięcia naprawy odciętych nerwów obwodowych; oraz axoguard nerw -nerw, norcine podśluzówkowy produkt ECM, który jest używany do owinięcia i ochrony uszkodzonych nerwów obwodowych, a także wzmacnia rekonstrukcję nerwów, jednocześnie zapobiegając przywiązaniu tkanki miękkiej. Jego produkty obejmują również Axoguard Nerv Cap, świńskiego produktu ECM podśluzówkowego, który służy do ochrony końca nerwu obwodowego, a także oddziela nerw od otaczającego środowiska w celu zmniejszenia rozwoju objawowego lub bolesnego neuraka; oraz membrana tkanki miękkiej Avive, przetworzona ludzka membrana pępowiny, która może być stosowana jako resorbowalna tkanka miękka w celu oddzielania tkanek w łóżku chirurgicznym. Ponadto firma oferuje Axotouch Dwupunktowy dyskryminator, narzędzie używane do pomiaru gęstości unerwienia pola powierzchni skóry. Zapewnia swoje produkty szpitalom, ośrodkom chirurgicznym i szpitalom wojskowym chirurgom rekonstrukcyjnym plastiku, chirurgach ortopedycznych i plastikowych oraz różnych chirurgach jamy ustnej i szczękowej w Stanach Zjednoczonych, Kanadzie, Niemczech, Wielkiej Brytanii i innych krajach europejskich, Korei Południowej i na granicy międzynarodowej. Axogen, Inc. ma siedzibę w Alachua na Florydzie.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 426
Giełda: NASDAQ Capital Market
Ilość akcji w obrocie: 94.1864
Ilość akcji: Brak danych
Debiut giełdowy: 1986-12-17
WWW: https://www.axogeninc.com
CEO: Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A.
Adres: 13631 Progress Boulevard
Siedziba: 32615 Alachua
ISIN: US05463X1063
Wskaźniki finansowe
Kapitalizacja (USD) 747 704 750
Aktywa: 191 985 000
Cena: 16.25
Wskaźnik Altman Z-Score: 3.3
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -162.5
Ilość akcji w obrocie: 94%
Średni wolumen: 1 275 481
Ilość akcji 46 012 600
Wskaźniki finansowe
Przychody TTM 180 856 000
Zobowiązania: 92 578 000
Przedział 52 tyg.: 9.22 - 21.0
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -0.1
P/E branży: 29.9
Beta: 1.129
Raport okresowy: 2025-11-06
WWW: https://www.axogeninc.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Erick DeVinney Chief Innovation Officer 557 896 1976
Mr. Nir Naor C.F.A., CPA, L.L.M., M.B.A. Chief Financial Officer 509 681 1975
Ms. Karen Zaderej Chairman, President & Chief Executive Officer 1 489 491 1962
Ms. Doris Quackenbush Vice President of Sales 0 0
Mr. Harold D. Tamayo Vice President of Finance & Investor Relations 0 0
Mr. Todd Puckett Vice President of Operations 0 0
Mr. Marc A. Began Executive Vice President, General Counsel & Chief Compliance Officer 0 1968
Mr. Jens Schroeder Kemp Chief Marketing Officer 0 0
Dr. Ivica Ducic M.D., Ph.D. Chief Medical Officer 0 0
Lista ETF z ekspozycją na akcje AxoGen, Inc.
Symbol ETF Ilość akcji Wartość
IWM 1 063 748 13 924 455
IWO 395 950 5 182 980
IHI 231 524 3 030 654
VTWO 221 615 2 404 522
SCHA 217 988 2 847 555
HTEC 210 879 0
FESM 191 703 2 490 221
XHE 175 825 2 394 167
VHT 124 772 1 353 776
DFAS 119 419 1 563 194
IWC 100 733 1 318 600
DFAC 84 608 1 107 518
VFMO 58 462 634 312
DRDR.L 50 466 499 990
2B78.DE 50 466 577 887
HEAL.L 50 466 660 594
ITOT 49 323 645 638
VTWG 38 617 418 994
PSC 28 413 371 926
WLDS.L 27 374 271 210
WSML.L 27 374 358 327
IUSN.DE 27 374 313 464
SCHB 25 831 339 685
AGES.L 23 011 227 980
2B77.DE 23 011 263 499
AGED.L 23 011 301 210
RSSL 22 559 295 297
FHLC 17 646 229 221
PRFZ 16 200 213 840
IWV 10 967 143 563
ISCG 10 550 138 098
EES 10 268 134 408
GSSC 8 030 94 432
XSU.TO 7 587 138 306
DFAU 7 441 97 402
FDHT 6 881 89 384
VMO.TO 5 974 88 444
UMDV.AS 5 952 77 906
OMFS 5 721 75 517
UWM 4 442 58 145
URTY 3 676 48 118
QQQS 3 491 46 081
IBRN 3 481 45 566
VTHR 3 165 34 340
DCOR 2 264 29 635
ISCB 1 765 23 100
DFSU 1 592 20 839
AFSM 1 077 13 505
XUU.TO 885 16 137
XGRO.TO 612 11 165
XBAL.TO 282 5 139
XUH.TO 131 1 724
XAW.TO 110 2 013
HDG 53 693
XCNS.TO 22 402
XTR.TO 5 69
PZW.TO 0 1 011
SC0K.DE 0 47 780
RTYS.L 0 54 531
Wiadomości dla AxoGen, Inc.
Tytuł Treść Źródło Aktualizacja Link
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates AxoGen (AXGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to loss of $0.06 per share a year ago. zacks.com 2025-05-08 13:30:46 Czytaj oryginał (ang.)
Axogen, Inc. Reports 2025 First Quarter Financial Results ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025. globenewswire.com 2025-05-08 11:05:00 Czytaj oryginał (ang.)
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025 ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. globenewswire.com 2025-04-24 12:04:00 Czytaj oryginał (ang.)
Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript Axogen, Inc. (NASDAQ:AXGN ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Jens Kemp - Chief Marketing Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer; and Jens Kemp, Chief Marketing Officer. seekingalpha.com 2025-02-25 15:58:30 Czytaj oryginał (ang.)
Axogen, Inc. To Host Analyst & Investor Day on March 4th ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, will hold its Analyst & Investor Day on March 4, 2025, between 9am-12pm Eastern. globenewswire.com 2025-02-25 09:10:00 Czytaj oryginał (ang.)
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2024 fourth quarter and full year financial results on Tuesday, February 25, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. globenewswire.com 2025-02-11 18:58:00 Czytaj oryginał (ang.)
AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out? AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2025-01-13 12:36:26 Czytaj oryginał (ang.)
AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last? AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com 2025-01-13 08:11:09 Czytaj oryginał (ang.)
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Craig Swandal, experienced medical device manufacturing executive, joins leadership team Craig Swandal, experienced medical device manufacturing executive, joins leadership team globenewswire.com 2025-01-10 19:00:00 Czytaj oryginał (ang.)
Axogen: Well Placed To Capitalize Growth At Higher Multiples Axogen: Well Placed To Capitalize Growth At Higher Multiples seekingalpha.com 2025-01-06 22:01:33 Czytaj oryginał (ang.)
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2024-12-24 12:16:09 Czytaj oryginał (ang.)
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year. zacks.com 2024-12-19 12:45:50 Czytaj oryginał (ang.)
All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2024-11-28 15:05:55 Czytaj oryginał (ang.)
How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% The mean of analysts' price targets for AxoGen (AXGN) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com 2024-11-25 12:56:20 Czytaj oryginał (ang.)
Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript Axogen, Inc (NASDAQ:AXGN ) Q3 2024 Results Conference Call November 7, 2024 8:00 AM ET Company Participants Michael Dale - Chairman and Chief Executive Officer Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Kratky - Leerink Partners Jayson Bedford - Raymond James Ross Osborn - Cantor Fitzgerald Dave Turkaly - Citizens JMP Operator Good morning, everyone. Joining me on today's call is Michael Dale, Axogen's Chief Executive Officer and Director; and Nir Naor, Chief Financial Officer. seekingalpha.com 2024-11-09 11:53:02 Czytaj oryginał (ang.)
AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains? AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com 2024-10-14 12:29:10 Czytaj oryginał (ang.)
First September Gains in 5 Years? Buy 3 Breakout Stocks Now Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today. zacks.com 2024-09-23 20:06:21 Czytaj oryginał (ang.)
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft® ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®. globenewswire.com 2024-09-06 11:00:00 Czytaj oryginał (ang.)
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2024-09-04 14:16:05 Czytaj oryginał (ang.)
What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com 2024-08-30 17:01:02 Czytaj oryginał (ang.)
Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? The mean of analysts' price targets for AxoGen (AXGN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com 2024-08-23 14:55:37 Czytaj oryginał (ang.)
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2024-08-19 14:15:49 Czytaj oryginał (ang.)
Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript AxoGen, Inc. (NASDAQ:AXGN ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Harold Tamayo - Vice President-Finance and Investor Relations Karen Zaderej - Chairman, Chief Executive Officer and President Nir Naor - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Michael Sarcone - Jefferies Catlin Cronin - Canaccord Genuity Jayson Bedford - Raymond James Dave Turkaly - Citizens JMP Operator Greetings, and welcome to the AxoGen, Inc. Reports 2024 Second Quarter Financial Results Call. At this time all participants are in a listen-only mode. seekingalpha.com 2024-08-08 18:10:23 Czytaj oryginał (ang.)
AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates AxoGen (AXGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago. zacks.com 2024-08-08 13:21:26 Czytaj oryginał (ang.)
Axogen, Inc. Announces New Leadership Appointments ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Michael Dale is appointed as chief executive officer and as a member of the Axogen Board of Directors effective August 9, 2024. He succeeds Karen Zaderej, who will remain in an advisory role for nine months. globenewswire.com 2024-08-08 11:05:00 Czytaj oryginał (ang.)
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-08-01 15:06:25 Czytaj oryginał (ang.)
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, before the market opens. Axogen management will host an investment-community conference call and webcast at 8 a.m. ET following the release. globenewswire.com 2024-07-23 11:00:00 Czytaj oryginał (ang.)
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock? AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com 2024-07-12 13:41:10 Czytaj oryginał (ang.)
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in connection with the hire of a new non-executive employee. globenewswire.com 2024-07-01 11:00:00 Czytaj oryginał (ang.)
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection. zacks.com 2024-06-25 17:55:20 Czytaj oryginał (ang.)